Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
58
WXXWY Quote, Financials, Valuation and Earnings
Last price:
$8.75
Seasonality move
:
9.23%
Day range:
$8.79 - $9.10
52-week range:
$4.14 - $11.21
Dividend yield:
0%
P/E ratio:
29.93x
P/S ratio:
6.60x
P/B ratio:
2.66x
Volume:
31.7K
Avg. volume:
75.6K
1-year change:
46.48%
Market cap:
$17.8B
Revenue:
$2.6B
EPS (TTM):
$0.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 10.78% | -4.05% | $39.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$8.75 | -- | $17.8B | 29.93x | $0.00 | 0% | 6.60x |
|
ASCLF
Ascletis Pharma, Inc.
|
$1.9400 | -- | $1.9B | -- | $0.00 | 0% | 5,781.16x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
VBIZF
Viva Biotech Holdings
|
$0.3434 | -- | $724.5M | 19.39x | $0.00 | 0% | 3.15x |
|
ZLAB
Zai Lab Ltd.
|
$18.37 | $39.10 | $2.1B | -- | $0.00 | 0% | 4.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | 0.176 | -- | 1.98x |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -2.953 | -- | 12.82x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.076 | 12.91% | 11.22x |
|
VBIZF
Viva Biotech Holdings
|
24.82% | -7.332 | -- | 1.26x |
|
ZLAB
Zai Lab Ltd.
|
23.86% | 0.191 | 11.48% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -- | -13.95% | -13.95% | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$65.6M | -$69.7M | -17.96% | -22.45% | -54.4% | -$19.1M |
WuXi Biologics (Cayman), Inc. vs. Competitors
-
Which has Higher Returns WXXWY or ASCLF?
Ascletis Pharma, Inc. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of --. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Ascletis Pharma, Inc.'s return on equity of -13.95%.
Company Gross Margin Earnings Per Share Invested Capital WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B ASCLFAscletis Pharma, Inc.-- -- $269.3M -
What do Analysts Say About WXXWY or ASCLF?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Ascletis Pharma, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman), Inc. has higher upside potential than Ascletis Pharma, Inc., analysts believe WuXi Biologics (Cayman), Inc. is more attractive than Ascletis Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WXXWYWuXi Biologics (Cayman), Inc.0 0 0 ASCLFAscletis Pharma, Inc.0 0 0 -
Is WXXWY or ASCLF More Risky?
WuXi Biologics (Cayman), Inc. has a beta of -0.063, which suggesting that the stock is 106.255% less volatile than S&P 500. In comparison Ascletis Pharma, Inc. has a beta of -18.693, suggesting its less volatile than the S&P 500 by 1969.268%.
-
Which is a Better Dividend Stock WXXWY or ASCLF?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascletis Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Ascletis Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXXWY or ASCLF?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Ascletis Pharma, Inc. quarterly revenues of --. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Ascletis Pharma, Inc.'s net income of --. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.93x while Ascletis Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.60x versus 5,781.16x for Ascletis Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXXWYWuXi Biologics (Cayman), Inc.6.60x 29.93x -- -- ASCLFAscletis Pharma, Inc.5,781.16x -- -- --
-
Which has Higher Returns WXXWY or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of --. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About WXXWY or SVA?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman), Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe WuXi Biologics (Cayman), Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WXXWYWuXi Biologics (Cayman), Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is WXXWY or SVA More Risky?
WuXi Biologics (Cayman), Inc. has a beta of -0.063, which suggesting that the stock is 106.255% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.790, suggesting its less volatile than the S&P 500 by 21.049%.
-
Which is a Better Dividend Stock WXXWY or SVA?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios WXXWY or SVA?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.93x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.60x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXXWYWuXi Biologics (Cayman), Inc.6.60x 29.93x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns WXXWY or VBIZF?
Viva Biotech Holdings has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of --. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Viva Biotech Holdings's return on equity of -1.8%.
Company Gross Margin Earnings Per Share Invested Capital WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B VBIZFViva Biotech Holdings-- -- $694.7M -
What do Analysts Say About WXXWY or VBIZF?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Viva Biotech Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that WuXi Biologics (Cayman), Inc. has higher upside potential than Viva Biotech Holdings, analysts believe WuXi Biologics (Cayman), Inc. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings WXXWYWuXi Biologics (Cayman), Inc.0 0 0 VBIZFViva Biotech Holdings0 0 0 -
Is WXXWY or VBIZF More Risky?
WuXi Biologics (Cayman), Inc. has a beta of -0.063, which suggesting that the stock is 106.255% less volatile than S&P 500. In comparison Viva Biotech Holdings has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.44%.
-
Which is a Better Dividend Stock WXXWY or VBIZF?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viva Biotech Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Viva Biotech Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXXWY or VBIZF?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Viva Biotech Holdings quarterly revenues of --. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Viva Biotech Holdings's net income of --. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.93x while Viva Biotech Holdings's PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.60x versus 3.15x for Viva Biotech Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXXWYWuXi Biologics (Cayman), Inc.6.60x 29.93x -- -- VBIZFViva Biotech Holdings3.15x 19.39x -- --
-
Which has Higher Returns WXXWY or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to WuXi Biologics (Cayman), Inc.'s net margin of -39.51%. WuXi Biologics (Cayman), Inc.'s return on equity of 7.53% beat Zai Lab Ltd.'s return on equity of -22.45%.
Company Gross Margin Earnings Per Share Invested Capital WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B ZLABZai Lab Ltd.51.15% -$0.46 $939.8M -
What do Analysts Say About WXXWY or ZLAB?
WuXi Biologics (Cayman), Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $39.10 which suggests that it could grow by 112.86%. Given that Zai Lab Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Zai Lab Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings WXXWYWuXi Biologics (Cayman), Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is WXXWY or ZLAB More Risky?
WuXi Biologics (Cayman), Inc. has a beta of -0.063, which suggesting that the stock is 106.255% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.611%.
-
Which is a Better Dividend Stock WXXWY or ZLAB?
WuXi Biologics (Cayman), Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WuXi Biologics (Cayman), Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WXXWY or ZLAB?
WuXi Biologics (Cayman), Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $128.2M. WuXi Biologics (Cayman), Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$50.6M. Notably, WuXi Biologics (Cayman), Inc.'s price-to-earnings ratio is 29.93x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WuXi Biologics (Cayman), Inc. is 6.60x versus 4.36x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WXXWYWuXi Biologics (Cayman), Inc.6.60x 29.93x -- -- ZLABZai Lab Ltd.4.36x -- $128.2M -$50.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
